AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26407603
Drug: ABT-436 500
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-436 500 mg
Trial: 26407603
Drug: ABT-436 800
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-436 800 mg
Trial: 26407603
Drug: ABT-436 200
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-436 200 mg (morning regimen)
Trial: 26407603
Drug: ABT-436 200
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-436 200 mg (evening regimen)
Trial: 20152042
Drug: Glucosamine sulphate
RxNorm normalized name: Glucosamine Sulfate 750 MG Oral Capsule [GLUCOSAMINE SULPHATE]
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine sulphate (1500 mg per day for 6 weeks) followed by a 12-week progressive walking program (3000 to 6000 steps/day)
Trial: 11177189
Drug: Low fat
RxNorm normalized name: Low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low fat content breakfast (L)
Trial: 6203288
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (opiate antagonist)
Trial: 23426563
Drug: Kinesio taping
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesio taping treatment for gastrocnemius muscle enhancement and ankle functional correction
Trial: 20664017
Drug: Electronic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Electronic insulin order template
Trial: 20664017
Drug: Usual insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual insulin ordering
Trial: 18246990
Drug: Coffee (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coffee (200 mg of caffeine)
Trial: 18246990
Drug: Placebo (decaffeinated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (decaffeinated coffee, 15 mg of caffeine)
Trial: 11515632
Drug: Flumazenil 2
RxNorm normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flumazenil 2 mg iv (group A)
Trial: 29264937
Drug: PCT-guided antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCT-guided antibiotic treatment
Trial: 26220089
Drug: Psychodynamic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychodynamic group therapy
Trial: 21427564
Drug: Acetylsalicylic acid
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acetylsalicylic acid (ASA) 1.5 mg/kg body weight/d
Trial: 14655198
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg plus 7 sevelamer hydrochloride 403 mg capsules (Arm B)
Trial: 14655198
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg plus 4 calcium acetate 667 mg tablets (Arm C)
Trial: 14655198
Drug: Ciprofloxacin 750
RxNorm normalized name: ciprofloxacin 750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 750 mg alone (Arm A)
Trial: 9262430
Drug: Coca chewing
RxNorm normalized name: ERYTHROXYLUM COCA LEAF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coca chewing (15 g of coca leaves)
Trial: 27105047
Drug: Atorvastatin 20
RxNorm normalized name: atorvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 20 mg/day (moderate intensity)
Trial: 27105047
Drug: Atorvastatin 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 60 mg/day (high intensity)
Trial: 10910027
Drug: Prednisolone (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone (mean dose 38 mg/day)
Trial: 8843769
Drug: Intravenous loxiglumide
RxNorm normalized name: Dexloxiglumide
DrugBank: Dexloxiglumide (DB04856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous loxiglumide
Trial: 3258993
Drug: co-trimoxazole (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: co-trimoxazole (160 mg trimethoprim plus 800 mg sulphamethoxazole) every 12 hours for 15 days
Trial: 3258993
Drug: cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cephalexin (500 mg) every 6 hours for 15 days
Trial: 29857271
Drug: DAPT (clopidogrel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAPT (clopidogrel + aspirin)
Trial: 27261980
Drug: Foot-bathing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot-bathing therapy at 40°C for 30 minutes daily for four weeks
Trial: 27261980
Drug: Foot-bathing therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foot-bathing therapy at 36.5°C for 30 minutes daily for four weeks (placebo)
Trial: 21057977
Drug: Ciprofloxacin (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (250 or 500 mg twice daily)
Trial: 20084975
Drug: Groups A
RxNorm normalized name: Meningococcal Polysaccharide Vaccine, Groups A, C Combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groups A and C conjugate Vaccine with MenB‐OMP
Trial: 20084975
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other vaccine)
Trial: 17454586
Drug: Chemotherapy (e.g.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (e.g. melphalan, thalidomide)
Trial: 17454586
Drug: High-dose treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose treatment with stem-cell support (autologous and allogeneic)
Trial: 31685285
Drug: TAU +
RxNorm normalized name: Interferon tau
DrugBank: Interferon tau (DB16972)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TAU + AE (treatment as usual + aerobic exercises)
Trial: 26293657
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy group intervention (n=9)
Trial: 12871871
Drug: Metformin (2.55
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (2.55 g/day) for 12 months
Trial: 12871871
Drug: Pioglitazone (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone (45 mg/day) + Metformin diet for 10 months
Trial: 12871871
Drug: Metformin diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin diet for 26 responders (N=26)
Trial: 10965008
Drug: Spinal cord
RxNorm normalized name: BOS TAURUS SPINAL CORD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal cord stimulation plus physical therapy
Trial: 7233297
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 (PGE) 4 mg administered as an intrarectal suppository
Trial: 7233297
Drug: Intravaginally administered
RxNorm normalized name: Intravaginal contraceptives
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravaginally administered PGE
Trial: 29116326
Drug: Single-Radius (SR)
RxNorm normalized name: radium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-Radius (SR) implant
Trial: 29116326
Drug: Multi-Radius (J-Curve,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-Radius (J-Curve, JC) implant
Trial: 1537636
Drug: Family therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Family therapy intervention
Trial: 20501479
Drug: Perindopril-indapamide (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril-indapamide (4 mg/1.25 mg)
Trial: 15735183
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injection (MDI) therapy with insulin aspart and insulin glargine
Trial: 8522408
Drug: Captopril 6.25
RxNorm normalized name: captopril 6.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 6.25 mg orally 15 min before thrombolysis
Trial: 28043754
Drug: High medication
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High medication adherence
Trial: 24976394
Drug: Quetiapine (to
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quetiapine (to 600 mg/d)
Trial: 22950430
Drug: Estrogen replacement
RxNorm normalized name: Norethindrone Acetate 1mg, Ethinyl Estradiol 5mcg Oral tablet [Estrogen Replacement/Osteoporosis]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen replacement therapy with 1 mg of estradiol hemihydrate (1 mg/day) orally for 6 months
Trial: 18719013
Drug: Combined hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combined hormone replacement therapy (HRT) - Conjugated equine oestrogen 0.625 mg plus medroxyprogesterone acetate 2.5/5.0 mg orally daily for one year
Trial: 15955017
Drug: Reimbursement for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reimbursement for nicotine replacement therapy, bupropion and behavioural counselling (intervention group)
Trial: 10352773
Drug: Dilute epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dilute epinephrine saline irrigation (1 mg/l)
Trial: 23009302
Drug: Managed controlled-opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Managed controlled-opioid prescription monitoring program
Trial: 18175829
Drug: Sublingual misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol 400 microg
Trial: 11230838
Drug: Atorvastatin 10
RxNorm normalized name: atorvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 10 mg/day (n = 730)
Trial: 11230838
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg/day (n = 694)
Trial: 8067763
Drug: Foscarnet (maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Foscarnet (maintenance therapy)
Trial: 28126707
Drug: Nurses' recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nurses' recommendations to intensify treatment
Trial: 28126707
Drug: Recommendations to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recommendations to start treatment
Trial: 28126707
Drug: Renal providers'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Renal providers' willingness to provide treatment
Trial: 26218871
Drug: Osmotic Release
RxNorm normalized name: nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Osmotic Release Oral System-Methylphenidate (OROS-MPH)
Trial: 10555127
Drug: Topotecan (dl-5)
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan (dl-5) and cytarabine (1 g/m2 over 2 hours; dl-5)
Trial: 10555127
Drug: Topotecan (d1-5)
RxNorm normalized name: PHOSPHOLIPASE D1
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan (d1-5) followed by etoposide (250 mg/m2 twice daily, d6-7)
Trial: 10555127
Drug: Etoposide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (250 mg/m2 twice daily dl-2) followed by topotecan (d3-d7)
Trial: 8670317
Drug: anti-CD5 ricin-linked
RxNorm normalized name: riboflavin 5'-phosphate
DrugBank: Flavin mononucleotide (DB03247)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: anti-CD5 ricin-linked immunoconjugate (CD5-IC) at doses up to 8 mg/m2/day for 4 days in 1 month
Trial: 19910627
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine (2.5 mg)
Trial: 11094007
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine and clonidine combination
Trial: 11094007
Drug: Intrathecal morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal morphine alone
Trial: 8880835
Drug: Opioid antagonist
RxNorm normalized name: OPIOID ANTAGONIST ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid antagonist naltrexone (low dose)
Trial: 8880835
Drug: Opioid antagonist
RxNorm normalized name: OPIOID ANTAGONIST ANALGESICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid antagonist naltrexone (high dose)
Trial: 19955827
Drug: Nebivolol added
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol added to antihypertensive treatment
Trial: 18818173
Drug: Intervention Group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention Group (n=100) - integrated intervention program including diabetes education, frequent blood glucose monitoring, nutritional counseling, meal plans with diabetes-specific nutritional meal replacement, and weekly progress updates
Trial: 12444889
Drug: ATD combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATD combined with l‐thyroxine (l‐T(4))
Trial: 12444889
Drug: TRAb positive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRAb positive after 12 Months of antithyroid therapy
Trial: 7584765
Drug: Dextromethorphan (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextromethorphan (40 mg)
Trial: 7584765
Drug: Placebo (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (10 mL sucrose)
Trial: 1901280
Drug: hMG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG therapy (alone or in combination with clomiphene citrate or gonadotropin‐releasing hormone agonist analog)
Trial: 1901280
Drug: hMG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG therapy in oligomenorrhea and PCOD patients
Trial: 1901280
Drug: hMG therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hMG therapy in hypogonadotropic amenorrhea patients
Trial: 6129142
Drug: Prenalterol (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (i.v. doses)
Trial: 6129142
Drug: Saline (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (i.v. doses)
Trial: 6129142
Drug: Prenalterol (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (inhaled doses)
Trial: 6129142
Drug: Saline (inhaled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline (inhaled doses)
Trial: 6129142
Drug: Terbutaline (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline (i.v. doses after prenalterol/saline)
Trial: 6129142
Drug: Prenalterol (i.v.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prenalterol (i.v. and inhaled doses)
Trial: 28598231
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of ursolic acid once a day for 12 weeks
Trial: 25579091
Drug: AK106‐001616 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK106‐001616 200 mg
Trial: 25579091
Drug: AK106‐001616 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK106‐001616 400 mg
Trial: 25579091
Drug: AK106‐001616 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AK106‐001616 600 mg
Trial: 21504953
Drug: Thermal stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thermal stimulation therapy (standard rehabilitation plus approximately 30-40 minutes of thermal stimulation daily for six weeks)
Trial: 19644227
Drug: Reboxetine (2-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reboxetine (2-8 mg/d)
Trial: 19644227
Drug: Methylphenidate (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (10-20 mg/d)
Trial: 9135360
Drug: midazolam 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.025 mg kg‐1 i.m.
Trial: 9135360
Drug: midazolam 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: midazolam 0.075 mg kg‐1 i.m.
Trial: 9135360
Drug: control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control (no midazolam administration)
Trial: 24239324
Drug: 0.75 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.75 mg/kg primaquine
Trial: 24239324
Drug: 0.4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg primaquine
Trial: 24239324
Drug: 0.1 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/kg primaquine
Trial: 23107470
Drug: Conventional Western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Western medicine and Bu‐Fei Jian‐Pi granules, Bu‐Fei Yi‐Shen granules, and Yi‐Qi Zi‐Shen granules
Trial: 18400400
Drug: Pregabalin (optimal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (optimal fixed dosages of 300, 450, 600 mg/d)
Trial: 12583552
Drug: 5-day treatment
RxNorm normalized name: 30 day Acne Treatment Kit KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-day treatment course with oral moxifloxacin (MXF)
Trial: 9640223
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human erythropoietin (rhEPO) at a dose of 150 U/kg/dose subcutaneously three times/week for a minimum of 12 weeks
Trial: 2530318
Drug: Circadian patterned
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circadian patterned variable rate infusion of floxuridine (FUDR)
Trial: 2530318
Drug: Constant rate
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant rate infusion of floxuridine (FUDR)
Trial: 2530318
Drug: Time-modified FUDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-modified FUDR infusion
Trial: 2530318
Drug: FUDR infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUDR infusion
Trial: 28343659
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg zinc oxide (n=144)
Trial: 28343659
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ferrous fumarate (n=148)
Trial: 21689865
Drug: Aerosolized buccal
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aerosolized buccal midazolam
Trial: 21689865
Drug: Aerosolized intranasal
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized intranasal midazolam
Trial: 16483431
Drug: Subcutaneous infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous infiltration of metronidazole (group B)
Trial: 12603860
Drug: Topical glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical glucocorticoid (clobetasol), applied for 3 days
Trial: 12603860
Drug: Topical applications
RxNorm normalized name: honey based topical applications
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical applications of an equimolar distribution of free fatty acids, cholesterol, and ceramides
Trial: 8165610
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (adapted doses, continuous intravenous)
Trial: 8165610
Drug: Enoxaparin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (1 mg/kg every twelve hours, subcutaneously)
Trial: 11697840
Drug: Weekly docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly docetaxel 36 mg/m2 i.v. administered weekly for six consecutive weeks followed by two weeks without treatment
Trial: 8151485
Drug: Lidocaine-prilocaine 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine-prilocaine 5% cream (EMLA)
Trial: 3143625
Drug: Total parenteral
RxNorm normalized name: TPN - total parenteral nutrition
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total parenteral nutrition and nil by mouth (n = 17)
Trial: 3143625
Drug: Defined formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Defined formula diet administered through a nasogastric tube (n = 19)
Trial: 3143625
Drug: Partial parenteral
RxNorm normalized name: rosin partially dimerized glycerol ester
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Partial parenteral nutrition and oral food (n = 15)
Trial: 28892156
Drug: Polydextrose (PDX)
RxNorm normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (PDX) in beverage at 0, 8, 12, and 16 g
Trial: 28892156
Drug: Polydextrose (PDX)
RxNorm normalized name: Polydextrose
DrugBank: Polydextrose (DB14836)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose (PDX) in bar at 0 and 12 g
Trial: 23017510
Drug: Saw palmetto
RxNorm normalized name: Saw palmetto
DrugBank: Saw palmetto (DB14360)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saw palmetto treatment
Trial: 16586079
Drug: Preserved flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preserved flow with decreased glucose metabolism
Trial: 16586079
Drug: Decreased flow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decreased flow with preserved glucose metabolism
Trial: 10970684
Drug: Chemotherapy combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy combined with SRL172 (Mycobacterium vaccae)
Trial: 1467127
Drug: Very low
RxNorm normalized name: Very low fat spread
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very low protein diet (0.4 g of protein/kg b.w./day) supplemented with essential amino acids
Trial: 1467127
Drug: Conventional low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional low protein diet (0.6 g of protein/kg b.w./day)
Trial: 19254671
Drug: Pyridostigmine (45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyridostigmine (45 mg, 3 times/day, for 24 hours)
Trial: 11750185
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of d-amphetamine